American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Roivant Sciences Ltd. (ROIV)

$41.85 +1.60% NASDAQ: ROIV · 15-min delayed

LONDON,
Public · NASDAQ: ROIV
721 employees
Founded 2014

Visit website Follow

$25.2BMarket cap

$8.3MRevenue · FY2026

-$299.8MNet income

721Employees

ROIVNASDAQ

2021IPO

About Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Founded: 2014
Type: Public · NASDAQ: ROIV
Employees: 721
IPO date: Oct 1, 2021
Headquarters: 7TH FLOOR, 50 BROADWAY
LONDON, SW1H 0DB
Phone: 441-295-5950
Industry: Pharmaceuticals
Website: Visit site

Incorporation record

Incorporated in: BM — outside the United States
Registered office: Hamilton, BM
Legal entity ID: 549300DL466NY5J6U724

Source: GLEIF, the global Legal Entity Identifier registry · checked Aug 8, 2026. A US headquarters does not always mean US incorporation.

Is Roivant Sciences Ltd. an American company? No. Roivant Sciences Ltd. is incorporated in Bermuda. It maintains US operations and its shares trade on NASDAQ — which is why it is often mistaken for a US company.

Registry IDs

Ticker: ROIV Nasdaq
SEC CIK: 1635088
LEI: 549300DL466NY5J6U724
EIN: 981173944
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Roivant Sciences Ltd.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/roivant-sciences-ltd/"><img src="https://americancompanies.com/badge/roivant-sciences-ltd.svg" alt="Roivant Sciences Ltd. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow Roivant Sciences Ltd. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2026: $8.3M
Net income: -$299.8M
Total assets: $5.7B
Market cap: $25.2B

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: ROIV

$41.85 +1.60%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$16.03 $41.85

52-week range

Market cap: $25.2B
Shares outstanding: 601.7M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Oct 1, 2021

Roivant Sciences Ltd. (ROIV) Stock Price

Reported a net loss of $299.8M in FY2026.
Trading near its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Roivant Sciences Ltd..

Write a review

Newsroom

News about Roivant Sciences Ltd.

Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue Estimates Zacks Investment Research · 2026-11-09 · positive Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 GlobeNewswire Inc. · 2026-10-21 · neutral Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU) GlobeNewswire Inc. · 2026-10-21 · positive Company News for Sep 9, 2026 Zacks Investment Research · 2026-09-09 · positive Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive Director GlobeNewswire Inc. · 2026-09-08 · neutral Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight GlobeNewswire Inc. · 2026-05-18 · positive

News & sentiment via Polygon.io

FAQ

Roivant Sciences Ltd.: frequently asked questions

Is Roivant Sciences Ltd. an American company?

No — Roivant Sciences Ltd. is not an American company. Roivant Sciences Ltd. is incorporated in Bermuda. It maintains US operations and its shares trade on NASDAQ — which is why it is often mistaken for a US company.

Where is Roivant Sciences Ltd. incorporated?

Roivant Sciences Ltd. is legally incorporated in Bermuda, according to its GLEIF legal-entity record.

Is Roivant Sciences Ltd. traded on a US stock exchange?

Yes — Roivant Sciences Ltd. trades under the ticker ROIV on the NASDAQ. A US stock listing does not by itself make a company American — incorporation and ownership are what this page reports.

Is Roivant Sciences Ltd. publicly traded?

Yes — Roivant Sciences Ltd. is a publicly traded company. Its stock trades under the ticker symbol ROIV on the NASDAQ.

What does Roivant Sciences Ltd. do?

Roivant Sciences Ltd. is an American Pharmaceuticals company in the Health & Beauty sector.

When was Roivant Sciences Ltd. founded?

Roivant Sciences Ltd. was founded in 2014.

Explore